GSK Deploys $10.6 Billion to Precision Oncology as Post-Haleon Strategy Crystallizes

GSK announced on June 9, 2026, an all-cash acquisition of Boston-based Nuvalent for $10.6 billion in aggregate equity value. The deal signals a deliberate capital reallocation: since spinning off consumer health as Haleon in 2022, GSK has repositioned toward specialty medicines and oncology—areas with durable pricing and high competitive barriers. Nuvalent brings three lung cancer candidates into GSK's portfolio. The valuation reflects a forward bet on pipeline optionality rather than near-term cash flows, consistent with large-cap pharma's structural need to offset patent expirations.